Eating Disorders News and Research

Latest Eating Disorders News and Research

Fussy eating may be an “eating disorder” say researchers

Picky and fussy eaters are not just being difficult to please say U.S. researchers. They may be suffering from an eating disorder like anorexia or bulimia. Soon the disorder is to have an official name and the American Psychiatric Association plans to call them “selective eaters”.

11 Jul 2010

Shire receives FDA approval of Daytrana for ADHD in adolescents

Shire plc, the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of Daytrana® (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years. Daytrana, the first and only transdermal ADHD patch, is already an FDA-approved ADHD treatment for children 6 to 12 years. Daytrana is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, and social).

7 Jul 2010

Virtual food can be used for evaluation and treatment of eating disorders: Researchers

Food presented in a virtual reality environment causes the same emotional responses as real food. Researchers writing in BioMed Central's open access journal Annals of General Psychiatry compared the responses of people with anorexia and bulimia, and a control group, to the virtual and real-life snacks, suggesting that virtual food can be used for the evaluation and treatment of eating disorders.

5 Jul 2010

Web sites that promote anorexia raise concern

For women with low self-esteem, poor body image and a certain genetic predisposition towards an eating disorder, the messages promoted on pro-eating disorder web sites can be similar to someone considering suicide finding a loaded gun on her pillow.

3 Jul 2010

Fera Pharmaceuticals launches Neptazanetm tablets for reducing intraocular pressure

Fera Pharmaceuticals is pleased to announce the launch of Neptazane (Methazolamide) 25 mg and 50 mg tablets. Both strengths are available in 90 count bottles.

3 Jul 2010

Elements Behavioral Health acquires The Ranch in Tennessee

Elements Behavioral Health, provider of residential treatment services for addiction and co-occurring disorders, announced this week the acquisition of The Ranch in Nunnelly, Tennessee. Elements is best known to the public as the owner of the internationally famous Promises Treatment Centers in Malibu and Los Angeles, where many Hollywood celebrities have been treated successfully for substance abuse.

2 Jul 2010

Women in early recovery gain new perspective on helping themselves by helping others

Women seeking to overcome an eating disorder or addiction still face numerous hurdles once they acknowledge their disease and commit to pursuing a path of recovery. Women with advanced or multiple interconnected diseases often seek inpatient or residential treatment, which gives them time to step back from the demands of daily life to focus solely on themselves.

1 Jul 2010

Majority of older women seek help for eating disorders

Eating disorders are equal-opportunity offenders – crossing economic and cultural boundaries and leaping the borders of age and gender. For a long time thought to be diseases affecting teens and young women in their 20s, eating disorder treatment centers nationwide are seeing an increase in the population of older women seeking help for eating disorders.

25 Jun 2010

Pfizer to discontinue commercial availability of Mylotarg for AML in U.S.

Pfizer Inc. announced today that based on discussions with the U.S. Food and Drug Administration (FDA), it will be discontinuing commercial availability of Mylotarg® (gemtuzumab ozogamicin for Injection) (used for the treatment of relapsed acute myeloid leukemia (AML)) in the United States and that it will be voluntarily withdrawing the new drug application (NDA) for Mylotarg effective October 15, 2010.

22 Jun 2010

$FDA approves Jevtana in combination with prednisone for metastatic hormone-refractory prostate cancer$

FDA approves Jevtana in combination with prednisone for metastatic hormone-refractory prostate cancer

Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) has granted marketing authorization for Jevtana® (cabazitaxel) Injection in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer (mHRPC) previously treated with a docetaxel-containing treatment regimen.

18 Jun 2010

New book gives hope to women and families who are in difficult stages of anorexia treatment

Women and families struggling with an eating disorder or another addiction should never lose sight of the need to sustain the spirit, according to a new book by Jena Morrow, an author in recovery after more than 20 years with anorexia nervosa. Morrow, a behavioral health specialist at Timberline Knolls Residential Treatment Center, details a battle with anorexia that begins in early childhood in Hollow: An Unpolished Tale, recently released by Moody Publishers.

17 Jun 2010

Clinical trials of four investigational compounds in solid tumors presented at ASCO Annual Meeting

Millennium: The Takeda Oncology Company today announced data from clinical trials of four investigational compounds in solid tumors presented at the Annual Meeting of the American Society of Clinical Oncology, held in Chicago, Illinois, June 4-8, 2010. These data include an oral presentation on MLN8237, the Company's selective Aurora A kinase inhibitor.

9 Jun 2010

Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO

Abraxis BioScience, Inc. announced today that findings from their phase 3 randomized trial of nanoparticle albumin bound driven chemotherapy, nab-paclitaxel (ABRAXANE for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) plus carboplatin, showed a statistically significant 31 percent improvement in overall response rate when compared with Taxol (paclitaxel) injection plus carboplatin in the first-line treatment of patients with non-small cell lung cancer.

8 Jun 2010

GTx presents quality of life results from Ostarine Phase IIb study in cancer cachexia patients at ASCO 2010

GTx, Inc. today presented additional results from the Ostarine™ Phase IIb study demonstrating an improvement in quality of life (fatigue and anorexia) in cancer patients with muscle wasting (cancer cachexia) who demonstrated improvement in functional performance as measured by stair climb. Ostarine (GTx-024) is GTx's lead selective androgen receptor modulator (SARM) which the company is developing for the treatment of cancer cachexia.

8 Jun 2010

Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations

Millennium: The Takeda Oncology Company today reported on data from oral presentations of VELCADE® (bortezomib) for Injection based therapy in multiple myeloma presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). These data highlight VELCADE based therapy in both transplant and non-transplant eligible previously untreated multiple myeloma patients, as well as VELCADE used as induction and/or maintenance therapy.

7 Jun 2010

AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer

Amgen today announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer. The results are being presented for the first time in an oral presentation at the 2010 American Society of Clinical Oncology Annual Meeting.

7 Jun 2010

ZymoGenetics' IL-21 Phase 2 clinical trial in metastatic melanoma meets primary endpoint

ZymoGenetics, Inc. today announced positive results from a Phase 2 clinical trial in metastatic melanoma with recombinant Interleukin 21 (IL-21) as a single agent. The trial met the primary endpoint of efficacy, as measured by objective response rate or lack of early disease progression. Overall response rate was 23.1%, in evaluable patients, and median progression-free survival was 4.3 months. The results were presented at the American Society of Clinical Oncology meeting.

7 Jun 2010

Estradiol plays role in development of eating disorders during puberty: MSU researchers

For the first time, scientists have discovered a possible biological culprit in the development of eating disorders during puberty: a type of estrogen called estradiol.

5 Jun 2010

Millennium announces data on VELCADE in treatment of patients with amyloidosis

Millennium: The Takeda Oncology Company today announced data examining the use of VELCADE in the treatment of patients with relapsed or refractory light chain (AL) amyloidosis. Amyloidosis is a rare condition in which excessive proteins build up in organs or tissues, such as the heart, kidney or liver. These data were presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Illinois, June 4-8, 2010.

5 Jun 2010

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Merck announced today results from a new non-inferiority trial of an antiemetic regimen containing fosaprepitant dimeglumine administered as a single intravenous (IV) 150-mg dose in combination with a 5-HT3 antagonist and dexamethasone compared with a three-day regimen of aprepitant with a 5-HT3 antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving a first cycle of cisplatin-based chemotherapy.

4 Jun 2010

Eating Disorders News and Research

Latest Eating Disorders News and Research

Fussy eating may be an “eating disorder” say researchers

Shire receives FDA approval of Daytrana for ADHD in adolescents

Virtual food can be used for evaluation and treatment of eating disorders: Researchers

Web sites that promote anorexia raise concern

Fera Pharmaceuticals launches Neptazanetm tablets for reducing intraocular pressure

Elements Behavioral Health acquires The Ranch in Tennessee

Women in early recovery gain new perspective on helping themselves by helping others

Majority of older women seek help for eating disorders

Pfizer to discontinue commercial availability of Mylotarg for AML in U.S.

FDA approves Jevtana in combination with prednisone for metastatic hormone-refractory prostate cancer

New book gives hope to women and families who are in difficult stages of anorexia treatment

Clinical trials of four investigational compounds in solid tumors presented at ASCO Annual Meeting

Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO

GTx presents quality of life results from Ostarine Phase IIb study in cancer cachexia patients at ASCO 2010

Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations

AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer

ZymoGenetics' IL-21 Phase 2 clinical trial in metastatic melanoma meets primary endpoint

Estradiol plays role in development of eating disorders during puberty: MSU researchers

Millennium announces data on VELCADE in treatment of patients with amyloidosis

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Eating Disorders News and Research

Latest Eating Disorders News and Research

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in